Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379197 · ClinicalTrials.gov registry record · Phase 2
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00379197 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 13 participants.
The verdict
NCT00379197, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast cancer by blocking the use of estrogen by the tumor cells. Naltrexone may also stop the growth of breast cancer by impairing blood flow to the tumor. PURPOSE: This phase II trial is studying how well naltrexone works in treating women with metastatic breast cancer that is no longer responsive to previous hormone therapy.
Interventions
- PROCEDURE PET scan
- DRUG naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379197
The ClinicalTrials.gov registry entry for NCT00379197 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET scan is the first listed.
NCT00379197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00379197 about?
NCT00379197 is a clinical study titled "Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast cancer by blocking the use of estrogen by the tumor cells. Naltrexone may also stop the growth of breast cancer by impairing blood flow to the tumor. PURPOSE: This phase II trial is studying how well naltre...
What is the current status of trial NCT00379197?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00379197?
The interventions under investigation include: PET scan (PROCEDURE), naltrexone (DRUG).
Who is sponsoring clinical trial NCT00379197?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.